illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Affimed
Company logo

Affimed | Sustainability Performance

https://www.affimed.com

Affimed NV is a biotechnology company that focuses on developing immunotherapies for cancer treatment. The company specializes in creating antibody-based therapies aimed at enhancing the body’s immune response against cancerous cells.

2000

Germany

51 - 200 employees

Biotechnology

$1M - 10M in revenue

Not profitable

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#4617
Overallⓘ
#255
in Germanyⓘ
#94
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

205 out of 244

Overview
Environmental
Digital emissionsEnergy consumption
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Formycon

Germany, Health Care, Biotechnology

Company logo
BRAIN Biotech

Germany, Health Care, Biotechnology

Company logo
Eppendorf

Germany, Health Care, Biotechnology

Renewable energy ⓘProportion of the company's total electricity consumption sourced from renewable sources, expressed as a percentage.
28%2021
Critical
Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
2.0M$, 2025▲3250% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
8.0M$, 2023▲412.5% YoY
R&D intensity ⓘResearch and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
375%2023

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

    Available in
    Scale package

    Access
  • Email
  • Email